{"id":1007348,"date":"2026-10-01T07:39:18","date_gmt":"2026-10-01T11:39:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/"},"modified":"2026-10-01T07:39:18","modified_gmt":"2026-10-01T11:39:18","slug":"ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/","title":{"rendered":"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BEDFORD, Mass., Oct.  01, 2026  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.<\/p>\n<p>\n        <strong>Upcoming Investor Conference<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>\n        <strong>Chardan 10<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Healthcare Conference<\/strong>:<br \/>Date: Tuesday, October 20, 2026<br \/>Fireside Chat: 9:45 AM ET<br \/>Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO<br \/>Location: New York, NY<\/p>\n<p>A live webcast of the Chardan fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.<\/p>\n<p>\n        <strong>Upcoming Scientific Conferences<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>\n        <strong>Eyecelerator @ AAO 2026: <\/strong>October 8, 2026<br \/>New Orleans, Louisiana<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt\">\n          <strong>Company Presentation: Ocular Therapeutix: Redefining the Retina Experience <\/strong><br \/>\n          <br \/>Session: Retina-Biologics, Diagnostics, &amp; AI Showcase<br \/>Session Date\/Time: Thursday, October 8, 2026, 1:43 \u2013 1:48 PM CT<br \/>Presenter: Peter K. Kaiser, MD, Chief Development Officer<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt\">\n          <strong>Panel Discussion: The Odyssey: Industry Heroes Seeking Safe Passages and Happy Returns<\/strong><br \/>\n          <br \/>Panel Date\/Time: Thursday, October 8, 2026, 3:45 \u2013 4:30 PM CT<br \/>Panelist: Pravin U. Dugel, MD, Executive Chairman, President and CEO<\/li>\n<\/ul>\n<p>\n        <strong>Innovate Retina: <\/strong>October 8, 2026<br \/>New Orleans, Louisiana<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt\">\n          <strong>Presentation: Sustained Hydrogel Delivery in Neovascular AMD: Topline Outcomes from the Phase 3 SOL-1 Trial with Hydrogel-Formulated Axpaxli<\/strong><br \/>\n          <br \/>Session: Ocular Gene Therapies &amp; Advanced Therapeutics<br \/>Session Date\/Time: Thursday, October 8, 2026, 5:35 \u2013 5:39 PM CT<br \/>Presenter: Arshad M. Khanani, MD, MA, FASRS<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt\">\n          <strong>Panel Discussion<\/strong><br \/>\n          <br \/>Session: Industry Insights &amp; Advanced Therapeutics<br \/>Panel Date\/Time: Thursday, October 8, 2026, 6:45 \u2013 7:15 PM CT<br \/>Panelist: Peter K. Kaiser, MD, Chief Development Officer<\/li>\n<\/ul>\n<p>\n        <strong>American Academy of Ophthalmology Retina Subspeciality Day:<\/strong> October 9 &#8211; 10, 2026 <br \/>New Orleans, Louisiana<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt\">\n          <strong>Presentation: Phase 3 Trial of OTX-TKI (SOL-1) for Wet AMD <\/strong><br \/>\n          <br \/>Session: Section X: Clinical Trial Updates, Part I<br \/>Presentation Date\/Time: Friday, October 9, 2026, 4:35 \u2013 4:40 PM CT<br \/>Presenter: Darius M. Moshfeghi, MD, FASRS<\/li>\n<\/ul>\n<p>\n        <strong>American Academy of Ophthalmology<\/strong>: October 9-12, 2026 <br \/>New Orleans, Louisiana<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Presentation: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control<\/strong><br \/>\n          <br \/>Session: Industry Showcase<br \/>Session Date\/Time:\u00a0Saturday, October 10, 2026, 11:30 AM \u2013 12:30 PM CT<br \/>Faculty: Arshad M. Khanani, MD, MA, FASRS; Mark R. Barakat, MD, FASRS; Dilsher S. Dhoot, MD, FASRS<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Presentation: SOL-1 Phase 3 Superiority Trial Evaluating Intravitreal Axitinib Hydrogel (OTX-TKI) in nAMD<\/strong><br \/>\n          <br \/>Presentation Date\/Time: Monday, October 12, 2026, 9:00 \u2013 9:07 AM CT<br \/>Presenter: Mark R. Barakat, MD, FASRS<\/li>\n<\/ul>\n<p>Exact medical conference presentation times may be subject to change.<\/p>\n<p>\n        <strong>About Ocular Therapeutix, Inc.<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI\u2122 (also known as OTX-TKI), Ocular\u2019s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA<sup>\u00ae<\/sup>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.<\/p>\n<p>Follow the Company on its website, LinkedIn, or X.<\/p>\n<p>DEXTENZA<sup>\u00ae<\/sup> is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v07bWl2qVoZX-6wd8xwfn1jMmutgB9KGcO-Q-fxL-6PcZmIfj5f8nGqTwy1QHceK8JnPrOX-FKRy2N2EENeXQ8WWNYm0oXfm2lyQljgHmBc=\" rel=\"nofollow\" target=\"_blank\">bslattery@ocutx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWI4NGExMTUtOTc5NS00ZDUxLWEyZTAtNGRmMzc4ZWRiMDI5LTEwMjI2MjktMjAyNi0xMC0wMS1lbg==\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference : Chardan 10 th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY A live webcast of the Chardan fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation. Upcoming Scientific Conferences : Eyecelerator @ AAO 2026: October &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007348","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference : Chardan 10 th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY A live webcast of the Chardan fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation. Upcoming Scientific Conferences : Eyecelerator @ AAO 2026: October &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-01T11:39:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences\",\"datePublished\":\"2026-10-01T11:39:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/\"},\"wordCount\":567,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=\",\"datePublished\":\"2026-10-01T11:39:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences - Market Newsdesk","og_description":"BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference : Chardan 10 th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY A live webcast of the Chardan fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation. Upcoming Scientific Conferences : Eyecelerator @ AAO 2026: October &hellip; Continue reading \"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-01T11:39:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences","datePublished":"2026-10-01T11:39:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/"},"wordCount":567,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/","name":"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=","datePublished":"2026-10-01T11:39:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzQ4NyM3ODczMzQyIzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-october-scientific-and-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Participate in October Scientific and Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007348"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007348\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}